Targeted alpha particle therapy using actinium-225 conjugates
CA 2422291 C · Owner: Ma, Dangshe · Inventors: Borchardt, Paul; Scheinberg, David; Mcdevitt, Michael
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides functionalized chelants and a method of treating cancerous cells with alpha particles comprising the step of administering a pharmacologically effective dose of an 225Ac conjugate comprising a functionalized chelant R is independently CHQCO2X; Q is independently hydrogen; C1-C4 alkyl or (C1-C2 alkyl) phenyl; X is independently hydrogen; benzyl or C1-C4 alkyl; Z1 is (CH2)nY where n is 1-10 and Y is an electrophilic or nucleophilic moiety and Z2 is R; or alternatively, Z1 is hydrogen and Z2 is a peptide linker composed of 1-10 amino acids; said Y or said peptide linker covalently attached to an antibody or fragment thereof, or other biologic molecule; or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 14, 2001 and granted March 8, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 14, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 14, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.